Patent application number | Description | Published |
20080262107 | Pharmaceutical Compositions With Enhanced Performance - Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability. | 10-23-2008 |
20090169583 | Solid Adsorbates of Hydrophobic Drugs - A solid pharmaceutical composition comprises a solid adsorbate comprising a hydrophobic drug, a lipophilic vehicle, and a porous substrate, wherein the hydrophobic drug and lipophilic vehicle are adsorbed to the porous substrate. | 07-02-2009 |
20100003331 | SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE - A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier. | 01-07-2010 |
20100062073 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein. | 03-11-2010 |
20100119603 | NANOPARTICLES COMPRISING A DRUG,ETHYCELLULOSE,AND A BILE SALT - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt. | 05-13-2010 |
20100119612 | NANOPARTICLES COMPRISING NON-CRYSTALLINE DRUG - A pharmaceutical composition comprises nanoparticles comprising a core of non-crystalline drug and surface stabilizers consisting of a phospholipid and a bile salt. | 05-13-2010 |
20100129447 | NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER - A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer. | 05-27-2010 |
20100215747 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS - A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers. | 08-26-2010 |
20100266692 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an anionic cellulosic polymer. | 10-21-2010 |
20100323014 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer. | 12-23-2010 |
20120264833 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE - Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability. | 10-18-2012 |